Publications
- Subcortical and Cortical Gray Matter Atrophy in a Large Sample of Patients with Clinically Isolated Syndrome and Early Relapsing-Remitting Multiple Sclerosis2012 | First Faculty of Medicine
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial2012 | First Faculty of Medicine
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial2012 | First Faculty of Medicine
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis2012 | First Faculty of Medicine
- Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome2012 | First Faculty of Medicine
- Interferon-beta or azathioprine as add-on therapies in patients with active multiple sclerosis2012 | First Faculty of Medicine
- Current treatment options in multiple sclerosis2011 | First Faculty of Medicine
- Fingolimod (drug)2011 | First Faculty of Medicine
- High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience2010 | First Faculty of Medicine, Third Faculty of Medicine
- Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study2010 | First Faculty of Medicine
Loading network view...